As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention. However, the MASH pharmacotherapy pipeline is expanding, said Adam Myer, MD, a faculty member in the University of Cincinnati College of Medicine.